{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lipton RB"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["e1365-e1377"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7274916"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["94(13)"],"pubmed_abstract":["<h4>Objective</h4>To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM).<h4>Methods</h4>The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12.<h4>Results</h4>Among treated participants (n = 1,072), baseline mean number of MMDs was ≈16.1 across groups. Treatment with eptinezumab 100 and 300 mg was associate"],"journal":["Neurology"],"pubmed_title":["Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2."],"pmcid":["PMC7274916"],"funding_grant_id":["NF-SI-0616-10031","NIHR201369"],"pubmed_authors":["Allan B","Biondi DM","Pederson S","Lipton RB","Hirman J","Goadsby PJ","Smith J","Schaeffler BA","Cady R"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.","description":"<h4>Objective</h4>To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM).<h4>Methods</h4>The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12.<h4>Results</h4>Among treated participants (n = 1,072), baseline mean number of MMDs was ≈16.1 across groups. Treatment with eptinezumab 100 and 300 mg was associate","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar","modification":"2025-04-19T11:51:19.443Z","creation":"2020-06-27T07:28:42Z"},"accession":"S-EPMC7274916","cross_references":{"pubmed":["32209650"],"doi":["10.1212/WNL.0000000000009169"]}}